Stock Day Media

September 27 2023

Rivalry Releases New Original Game ‘Cash & Dash’ to Establish Next Generation of Casino Entertainment

Alexandria LeBlanc Other Corner Sep 27th, 2023

TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for Millennials and Gen Z, today released ‘Cash & Dash,’ a new original casino game available exclusively on Rivalry. Developed in-house by Rivalry’s games team, the fast-paced title blends elevated graphics, unique gameplay, and original IP to adapt the online casino experience for the next generation of bettors and their unique entertainment preferences.

“Online betting is still far behind other forms of entertainment from a product standpoint,” said Steven Salz, Co-Founder and CEO, Rivalry. “We see a growing opportunity to create betting products that are strikingly fun, interactive, and engaging, and our original games are a big step in that direction. Cash & Dash, Rushlane, and other original games we currently have in development, continue to build on a unique betting experience exclusive to Rivalry that differentiates our product at a time where most sportsbooks look and feel the same.”

Cash & Dash is a 3D game where players must infiltrate a high-security bank and avoid a series of booby-traps in order to steal the treasure and escape. Players bet the desired amount at the beginning of each round with multipliers that increase their winnings as they successfully navigate further into the secured building. Cash & Dash also features an array of Rivalry’s original IP as playable characters and more, further bridging product, marketing, and brand across the Company.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

As a live-service game, Cash & Dash offers players a dynamic gaming experience where additional content and rewards including new playable characters, custom maps, consumable items, and more will be released through future updates and expansions. Rivalry will also host limited-time events in collaboration with its creator partners to drive awareness and player engagement.

“Cash & Dash is a first-of-its-kind title that merges online casino betting with modern video game studio development and gameplay,” said Andre Nogueira, Senior Product Manager, Games, Rivalry. “We’ve incorporated tried-and-true mechanics from the games industry to add a layer of entertainment value to the casino experience that resonates with our Millennial and Gen Z audience.”

Cash & Dash has been developed by Rivalry’s growing team of game developers, designers, and motion artists with experience producing video games for publishers and studios including Xbox, Nintendo, Ubisoft, and more. Rivalry will continue investing in video game development and producing more first-party games which build on the on-site entertainment experience and create an online betting product unique to the Company.

Cash & Dash is available on desktop and mobile in select regions and will soon roll out to all of Rivalry’s markets globally.

About Rivalry
Rivalry Corp. wholly owns and operates Rivalry Limited, a leading sport betting and media company offering fully regulated online wagering on esports, traditional sports, and casino for the next generation of fans. Based in Toronto, Rivalry operates a global team in more than 20 countries and growing. Rivalry Limited has held an Isle of Man license since 2018, considered one of the premier online gambling jurisdictions. Rivalry also holds a sports bookmaker license in Australia and an internet gaming registration in Ontario, and is currently in the process of obtaining additional country licenses. Rivalry’s sportsbook is built on a proprietary tech stack and features a variety of originally developed products geared for Millennial and Gen Z fans including Same Game Combos, an esports parlay product, original casino games, and an interactive casino platform, Casino.exe.

Company Contact:
Steven Salz, Co-founder & CEO
ss@rivalry.com
416-565-4713

Investor Contact:
Oakstrom Advisors
Jeff Codispodi
investors@rivalry.com

Media Contact:
Cody Luongo, PR & Communications
cody@rivalry.com
203-947-1936

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “project” and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions “may” or “will” occur. These statements are only predictions.

Forward-looking statements are based on the opinions and estimates of management of the Company at the date the statements are made based on information then available to the Company. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Such factors, among other things, include regulatory or political change such as changes in applicable laws and regulations; the ability to obtain and maintain required licenses; the esports and sports betting industry being a heavily regulated industry; the complex and evolving regulatory environment for the online gaming and online gambling industry; the success of esports and other betting products are not guaranteed; changes in public perception of the esports and online gambling industry; failure to retain or add customers; the Company having a limited operating history; negative cash flow from operations; operational risks; cybersecurity risks; reliance on management; reliance on third parties and third-party networks; exchange rate risks; risks related to cryptocurrency transactions; risk of intellectual property infringement or invalid claims; the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and general economic, market and business conditions. For additional risks, please see the Company’s annual information form for the year ended December 31, 2022 and other disclosure documents available on SEDAR+ at www.sedarplus.ca.

No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Source: Rivalry Corp.

September 27 2023

Silver Mountain Discovers New High Grade Copper Vein and Hits Impressive Precious Metal Grades at Its Reliquias Mine, Peru

Alexandria LeBlanc Minning Pit Sep 27th, 2023

Key Highlights – Initial drilling on the Natividad Vein and mineral resource expansion drilling at Sacasipuedes vein system

Drill Hole SMR135-23-SCS (newly identified Natividad, or “NAT” vein)
1.55 m @ 81 g/t Ag, 2.51% Pb, 4.57% Zn, 1.80% Cu and 0.25 g/t Au, including
1.00 m @ 106 g/t Ag, 3.37% Pb, 5.84% Zn, 2.56% Cu and 0.09 g/t Au

Drill Hole SMR140-23-SCS (NAT vein)
2.20 m @ 42 g/t Ag, 2.79% Pb, 3.84% Zn, 0.75% Cu and 0.06 g/t Au, including
1.00 m @ 62 g/t Ag, 5.40% Pb, 4.70% Zn, 0.98% Cu and 0.06 g/t Au

Drill Hole SMR140-23-SCS (mineralized breccia)
0.60 m @ 1,319.55 g/t Ag, 0.86% Pb, 2.82% Zn, 0.03% Cu and 6.19 g/t Au, including
0.30 m @ 2,623.00 g/t Ag, 1.68% Pb, 5.60% Zn, 0.06% Cu and 12.20 g/t Au

TORONTO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Silver Mountain Resources Inc. (“Silver Mountain” or “the Company”) (TSXV: AGMR; OTCQB: AGMRF) is pleased to announce the discovery of the Natividad vein, a new copper rich vein at its 100% owned Reliquias mine, central Peru. Results from three of the initial four drill holes completed at Natividad have been received, all part of Phase 2 of the Company´s 2023 infill and resource expansion program. Drilling has also hit very high gold and silver grades near the Sacasipuedes vein, within a mineralized breccia body with strong argillic alteration.

Alvaro Espinoza, CEO of Silver Mountain, stated, “It is very exciting to have discovered a new mineralized vein, which has been named by our technical team as Natividad (or “NAT”). It is early days still, and the high grade copper values and true thickness observed augur well for its possible incorporation into a future mine plan. Our geologists are adapting the program to further test this structure along strike and at depth, and we will provide results as we receive them. Discovering a new vein in a historic district such as Reliquias proves once again that this project not only has a solid resource base on which to prepare a mine plan to re-start operations, but also has significant exploration upside to grow it further.”

Mr Espinoza continued, “The extremely high silver and gold grades found above the main Sacasipuedes vein is also exciting as it proves, once again, that bonanza type grades exist outside of the current mineral resource boundaries. We look forward to test the continuity of this new high grade hit in our ongoing underground drill program.”

Phase 2 of the 2023 drill program consists of 12,500 metres of NQ and HQ drilling aimed at infilling and growing the Company´s current mineral resource estimate (see news release dated April 12^th, 2023 ). So far, drilling crews have completed approximately 7,600 metres of this program with two underground rigs, and the Company has received results from 18 drill holes (see also news releases dated July 19^th and August 16^th, 2023).

Discussion of 2023 Drilling Results

The Company has so far completed 22 drill holes on the Sacasipuedes and Perseguida vein systems from three underground drill platforms, two from Sacasipuedes and one from Perseguida. The Natividad discovery was made through drilling originally aimed at the Sacasipuedes vein, the results of which are also included in this release. Details on the location of the underground drill platforms and drill traces are found in Figure 1. Table 1 also shows a summary of the results announced in this news release.

Drill Hole Location Map of the 2023 Drill program

Figure 1: Drill Hole Location Map of the 2023 Drill program

Number

Drill Platform

Hole ID

From

Interval

True Width¹

Gold

Silver

Lead

Zinc

Copper

Ag_Eq²

Vein

Number

Drill Platform

Drill hole

g/t

Oz/t

C-39

SMR-135-23-SCS

427.25

428.00

0.75

0.67

1.11

5.63

0.30

0.59

0.06

3.70

SCS

including

427.60

428.00

0.40

2.05

3.90

0.24

0.42

0.05

5.72

493.95

495.50

1.55

1.36

0.25

80.98

2.51

4.57

1.80

13.58

NAT

including

493.95

494.95

1.00

0.09

106.00

3.37

5.84

2.56

17.67

C-39

SMR-140-23-SCS

105.25

105.85

0.60

6.19

1319.55

0.86

2.82

0.03

60.31

including

105.25

105.55

0.30

12.20

2623.00

1.68

5.60

0.06

119.63

443.95

444.45

0.50

0.41

0.06

79.10

7.39

13.19

0.43

20.07

SCS

540.25

542.45

2.20

1.76

0.06

42.03

2.79

3.84

0.75

8.69

NAT

including

540.25

541.25

1.00

0.80

0.06

61.80

5.40

4.70

0.98

12.61

C-33

SMR-146-23-SCS

303.00

303.65

0.65

0.49

0.04

28.50

0.25

0.34

0.17

1.94

SCS

462.55

463.20

0.65

0.62

0.04

49.60

4.36

2.20

0.40

7.83

NAT

Notes
¹True thicknesses are shown only where they can be determined.
² Silver equivalent (Ag_Eq) grades are calculated using metal prices of: silver US$23.30/oz., gold US$1764/oz, copper US$9419/tm, lead US$2188/tm and zinc US$2813/tm. Silver equivalent grade is calculated as Ag_Eq (oz/t) = (Ag (oz/t) + (Au (g/t) * 2.40) + (Cu (%) * 2.70) + (Pb (%) * 0.80) + (Zn (%) * 0.80). Metal recoveries have not been applied in the silver equivalent value calculation.

Table 1: Location and summary of results from the Natividad vein

The Natividad vein is a newly identified mineralized structure found up to 100 metres below the Sacasipuedes vein (“SCS”). Company geologists believe that Natividad´s strike is oblique to the SCS vein, likely subparallel to the Matacaballo vein, and with a northerly dip. The mineralization is similar to the other veins in Reliquias, but with significantly higher quantities of chalcopyrite resulting in much higher grade copper grades than observed elsewhere. Company geologists interpret this style of mineralization as a separate event to the other veins drilled so far at Reliquias, suggesting that this deposit hosts a long-lived and multi-phase mineralization system. The Natividad vein has now been identified in four drill holes, spaced up to approximately 85 metres apart, and further drilling along strike and at depth is planned. Drilling has so far tested approximately 150 metres of strike length of Natividad, and it remains open laterally and vertically. Results from three drill holes have been received and are shown in Figure 2, a longitudinal section of the Natividad vein with the four completed drill holes.

Before hitting the Natividad vein, drill hole SMS-140-23-SCS intersected very high grade silver-gold at a shallow depth and high grade zinc-lead mineralization on the Sacasipuedes (“SCS”). The shallower precious metal mineralization is hosted in an argillically altered breccia with disseminated sulfides (see Figure 3), yielding some of the highest grade silver-gold grades seen so far at Reliquias, with a silver equivalent grade of approximately 120 oz/t AgEq. Company geologists are currently working on the interpretation of this style of mineralization. Further drilling will be needed to determine if this breccia is linked to the the Sacasipuedes vein system, or if it represents a new style of mineralization. The main Sacasipuedes intercept sits approximately 500 metres to the southeast of the outer limit of the current mineral resource, and below the lowest levels of the Reliquias mine historical workings. The SCS vein intercept of 0.50 metres with a combined Pb+Zn grade of 20.58%, is one the highest grade polymetallic results found to date. Further drilling is planned to test the lateral and down dip extensions of this intercept. Figure 4 shows a longitudinal section of the SCS vein with the location of this drill hole.

Longitudinal section of the newly identified Natividad vein

Silver equivalent (Ag_Eq) grades are calculated using metal prices of: silver US$23.30/oz., gold US$1764/oz, copper US$9419/tm, lead US$2188/tm and zinc US$2813/tm. Silver equivalent grade is calculated as Ag_Eq (oz/t) = (Ag (oz/t) + (Au (g/t) * 2.40) + (Cu (%) * 2.70) + (Pb (%) * 0.80) + (Zn (%) * 0.80). Metal recoveries have not been applied in the silver equivalent value calculation.

Figure 2: Longitudinal section of the newly identified Natividad vein

High grade Ag-Au intercept in drill hole SMR140-23-SCS

Figure 3: High grade Ag-Au intercept in drill hole SMR140-23-SCS

Longitudinal section of the Sacasipuedes vein showing grade-thickness values

Figure 4: Longitudinal section of the Sacasipuedes vein showing grade-thickness values

The 2023 drill program consists of two phases: an initial 3,500 metre phase using BQ diameter core (now completed); and a second 12,500 meter phase using NQ and HQ diameter core. Full results from the BQ diameter drilling have now been announced (see also March 29^th and July 19^th news release at https://agmr.ca/news/). The second phase of infill drilling started in June 2023 and continues with 3 rigs working in the upper levels of the MTC (Matacaballo), MTS (Meteysaca), PER (Perseguida), and SCS (Sacasipuedes) vein systems, where high grade historical resource blocks remain outside of the current resource estimate. The Company plans to incorporate these high-grade blocks in future resource estimates. Results will be announced as they become available.

On Behalf of the Board of Directors of Silver Mountain Resources Inc.

Alvaro Espinoza, Chief Executive Officer

Qualified Person

Antonio Cruz Bermudez, , P. Geo. Registered Member MAIG is an independent consultant of the Company and the Qualified Person (within the meaning of NI 43-101) responsible for the MRE, has reviewed and approved the scientific and technical information contained in this news release.

About Silver Mountain

Silver Mountain Resources Inc. is a silver explorer and mine developer planning to restart production at the Reliquias underground mine and currently exploring its 100% owned Castrovirreyna Project, consisting of over 60,000 hectares of highly prospective mineral claims and concessions located in the Huancavelica Region, central Peru. For additional information regarding the Castrovirreyna Project, please refer to the Company’s technical report, titled NI 43-101 Technical Report Mineral Resource Estimate for the Reliquias Mine, Huancavelica- Peru, dated March 27, 2023, effective date March 18, 2023, available at https://sedar.com.

For further information about our drill program, including cross sections of the main veins with drill hole locations, please refer to our corporate presentation, available on our website at www.agmr.ca

For Further Information Contact:

Alvaro Espinoza
Chief Executive Officer
aespinoza@agmr.ca
Silver Mountain Resources Inc
82 Richmond Street East
Toronto, ON M5C 1P1
+51 954 475 319

info@agmr.ca
www.agmr.ca

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sampling, QA/QC, and Analytical Procedures

Silver Mountain follows systematic and rigorous sampling and analytical protocols which meet industry standards. These protocols are summarized below.

All drill holes are diamond core holes with BQ, HQ or NQ core diameters. Drill core is collected at the underground drill site where recovery measurements are taken before the core is transported by truck to the core logging facility at the Caudalosa Grande mine camp, where it is photographed and geologically logged. The core is then cut in half with a diamond saw blade with half the sample retained in the core box for future reference and the other half placed into a pre-labelled plastic bag, sealed with a plastic zip tie, and identified with a unique sample number. The core is typically sampled over a 1 – 2 metre sample interval unless the geologist determines the presence of an important geological contact. The bagged samples are then stored in a secure area pending shipment to a certified laboratory sample preparation facility.

Rock channel samples were collected with an electric percussion hammer and do not exceed 1.0 m in length. Channels are broken at obvious geologic boundaries to correctly separate rock types and mineralization styles. The sample bags were sealed with a plastic zip tie and identified with a unique sample number, pending shipment to a certified laboratory sample preparation facility.

Samples are sent by batch to the ALS laboratory in Lima for assay. Silver Mountain independently inserts certified control standards, fine and coarse blanks, and duplicates into the sample stream to monitor data quality. These standards are inserted “blindly” to the laboratory in the sample sequence prior to departure from the core storage facilities. At the laboratory, samples are dried, crushed, and pulverized and then analyzed using a fire assay-AA finish analysis for gold and a full multi-acid digestion with ICP-AES analysis for other elements. Samples with results that exceed maximum detection values for the main elements of interest (Ag, Zn, Pb, Cu) are re-analyzed using precise ore-grade ICP analytical techniques, while high gold values are re-analyzed by fire assay with a gravimetric finish.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements“) that relate to Silver Mountain’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result”, “are expected to”, “expects”, “will continue”, “is anticipated”, “anticipates”, “believes”, “estimated”, “intends”, “plans”, “forecast”, “projection”, “strategy”, “objective” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Silver Mountain’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the factors set forth under “Caution Regarding Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form dated August 14, 2023, and other disclosure documents available on the Company’s profile on SEDAR+ at www.sedarplus.ca. Silver Mountain undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Silver Mountain to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/1e5f699f-117b-4004-96ef-60295828313d

https://www.globenewswire.com/NewsRoom/AttachmentNg/4bfbf7e4-35c8-4c71-a40c-67fa27780f5d

https://www.globenewswire.com/NewsRoom/AttachmentNg/e215dd31-f142-44c0-991e-74774df63d29

https://www.globenewswire.com/NewsRoom/AttachmentNg/aeaa42ef-c995-4fca-9187-d5ae5849fce3

September 27 2023

VALEO PHARMA ENTERS INTO $5 MILLION CREDIT FACILITY AGREEMENT WITH ACCORD FINANCIAL INC.

Alexandria LeBlanc Biotech Corner Sep 27th, 2023

MONTREAL, Sept. 27, 2023 /CNW/ – Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (“Valeo” or the “Company“), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc.

The $5 million credit facility is secured by a first rank lien on the Corporation’s short term assets, and bears interest at the Scotiabank’s prime rate plus an applicable margin. Borrowings under the credit facility are expected to be used for working capital and other general corporate purposes.

“Securing this new credit facility provides us with additional financial liquidity and increased flexibility to support our long-term growth strategy,” said Luc Mainville, CFO. “Accessing non-dilutive capital to augment our existing cash reserve is an important milestone as we accelerate our path towards profitability.”

About Valeo Pharma Inc.

Valeo Pharma is a fast growing Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.

Forward Looking Statements

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

SOURCE Valeo Pharma Inc.

Breaking news background. Vector template for your design illustration

September 27 2023

US Nuclear: Introduction of Revolutionary Desalination and RAD Waste Water Treatment Techniques

Alexandria LeBlanc Featured Content Sep 27th, 2023

LOS ANGELES, CA, Sept. 25, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — US Nuclear Corp. (OTC-QB: UCLE) and Arbok-Nuclear (an NTAC company), have recently formed a highly beneficial Strategic Alliance for the purpose of bringing to market amazing improvements to desalination plants and rad-wastewater treatment. This strategic alliance makes US Nuclear a substantially more important nuclear power plant vendor and enables them to sell more radiation detectors. This is an especially good fit with USN’s unique and unchallenged line of radiation water monitors NEXGEN-SSS and NEXGEN-SEA. USN is the leader in this market because of the difficulty of the task along with their top engineering fabrication staff.

20% of the world’s population do not have adequate access to safe drinking water. We all know that access to safe drinking water is a huge problem in undeveloped areas with poor sanitation and also rich desert areas and big cities as well. Desalination projects are often paired with nuclear power plants and can be symbiotic. The power plant provides the needed electricity and the waste heat facilitates the desalination process, while the desalination plant provides fresh, clean cooling water. Arbok Nuclear has developed patented technology to remove dangerous radioisotopes from NPP cooling and process water, waste water, and other water sources, in addition to providing desalination technology which is 30% less costly and has double the output than traditional technologies. Arbok’s desalination plant produces pure drinking quality water useful to the NPPs for cooling, and does so at a fraction of the price using as much as 10 times less energy than reverse osmosis. With reverse osmosis, 50% or more of the water taken from the sea, is transformed into a toxic brine, but Arbok has no waste and 100% of the water is desalinated while the salt and other contaminants are collected as a dry powder which can be easily disposed of. Notably, Arbok’s purification method is the only one available that can remove ALL radioisotopes, even including tritium, which has been a large issue with the Fukushima releases. Arbok’s radioisotope removal and desalination technology has been tested at multiple NPPs and research institutes and was determined to fully meet the requirements for use.

USN’s radiation water monitors are already popular at desalination plants for measuring input and output water, as well as detecting cooling water leaks from local NPPs. Through this strategic alliance, USN will ramp up sales revenue by gaining additional exposure to the nuclear power plant market globally and by providing their radiation detectors as part of a turnkey package with Arbok Nuclear’s radiation removal and desalination technologies.

Safe Harbor Act

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com.

CONTACT:

US Nuclear Corp. (OTC-QB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Michael Hastings, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com

September 26 2023

Armanino Foods of Distinction, Inc. Maintains Its Regular Quarterly Dividend of $.033 Per Share

Alexandria LeBlanc Other Corner Sep 26th, 2023

Armanino Foods of Distinction, Inc. (OTC Pink: AMNF) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.033 per share. The dividend will be payable to shareholders of record on October 6, 2023, and will be disbursed on or about October 31, 2023. This is the Company’s 93rd consecutive quarterly dividend. In addition, the Company has had ten special dividends.

Douglas R. Nichols, Chairman of the Board stated, “The Board is confident in management’s ability to continue to outpace industry norms for strategic positioning, operational efficiency, and financial results. As a result, we remain committed to continue supporting the current quarterly dividend of $0.033 per share which represents the highest dividend payout on a per-share basis in our Company’s history.”

Tim Anderson, President, and CEO commented, “We are anticipating that third quarter and year to date sales and profits will continue to exceed prior year’s record results. Significant progress has been made toward strategically strengthening our core business while simultaneously investing in new products and markets to meet evolving consumer needs. Armanino Foods is well-positioned to continue investing in diversified channels to capitalize on industry growth trends and to pursue financially accretive opportunities in adjacent markets. In addition, we are confident that our current capital expenditure project will continue to improve our manufacturing processes and increase cost efficiencies including the reduction of COGS to help mitigate future economic headwinds.”

Anderson concluded, “Given the strength of our balance sheet, we remain committed to making appropriate investments in our efforts to grow sales profitably with a focus on new products, new markets, operational efficiencies, and potential acquisitions.”

Armanino Foods of Distinction, Inc. is an international food company that manufactures and markets frozen Italian specialty food items to the foodservice, retail, and industrial markets. In addition to a classic Basil Pesto, Armanino offers other flavors and sauces including as Cilantro, Dried Tomato & Garlic, Roasted Red Bell Pepper, Southwest Chipotle, Artichoke, Roasted Garlic, Light Basil Pesto, Chimichurri, Harissa, Bolognese, and Alfredo. Armanino’s organic line includes classic Basil Pesto. Finally, Armanino Foods also offers cheese shakers, frozen pastas, and meatballs.

Cautionary Statements Regarding Forward-Looking Information

The declaration of cash dividends in the future, pursuant to the Company’s dividend policy, is subject to final determination each quarter by the Board of Directors based on a number of factors, including the Company’s financial performance and its available cash resources. For this reason, as well as others, there can be no assurance that dividends in the future will be equal or similar to the amount described in this press release or that the Board of Directors will not decide to suspend or discontinue the payment of cash dividends in the future.

Statements in this news release regarding our expectations and beliefs about our future financial performance and trends in our markets are “forward- looking statements” as defined in the Private Securities Litigations Reform Act of 1995. Forward-looking statements often include the words “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” or words of similar meaning, or future or conditional verbs such as “will,” “would,” “should,” “could,” or “may.”

The forward-looking statements in this news release regarding our future financial performance are based on current information and because our business is subject to several risks and uncertainties, actual operating results in the future may differ significantly from the future financial performance expected at the current time. Those risks and uncertainties may include, among others: economic factors affecting consumer confidence and discretionary spending and reducing the consumption of food prepared away from home; the extent and duration of the negative impact of the COVID-19 pandemic and its consequences on the Company; cost inflation/deflation and commodity volatility; competition; reliance on third party suppliers and interruption of product supply or increases in product costs; changes in the Company’s relationships with customers and group purchasing organizations; the Company’s ability to increase or maintain the highest margin portions of the Company’s business; achievement of expected benefits from cost savings initiatives; increases in fuel costs; changes in consumer eating habits; cost and pricing structures and other governmental regulation, including actions taken by national, state and local governments to contain and/or respond to the COVID-19 pandemic and its consequences; product recalls and product liability claims; and our reputation in the industry. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on information and estimates available to the Company at this time. We undertake no obligation to update or revise any forward-looking statements, except as may be required by law.

The best source of information on the company is the OTC Markets website (http://www.otcmarkets.com/stock/AMNF/company-info).

September 26 2023

Verano to Report Third Quarter 2023 Financial Results on November 8, 2023

Alexandria LeBlanc Cannabis Corner Sep 26th, 2023

CHICAGO, Sept. 26, 2023 (GLOBE NEWSWIRE) — Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial results for the third quarter ending September 30, 2023, before the market opens on Wednesday, November 8, 2023.

A conference call and webcast with analysts and investors is scheduled for November 8, 2023 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results and answer investor and participant questions.

Investors and participants can register in advance for the call by visiting: https://conferencingportals.com/event/sxTSCKLn
After registering, instructions will be shared on how to join the call for those who wish to dial in.
On November 8, 2023, the live webcast can be accessed via the following link: https://events.q4inc.com/attendee/254800729
The live and archived webcast will be available on the Events and Presentations page of the Company’s investor relations website at investors.verano.com.

About Verano
Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano offers a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf^™ and MÜV^™ dispensary banners and produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano^™, MÜV^™, Savvy^™, BITS^™, Encore^™, and Avexia^™. Verano’s active operations span 13 U.S. states, comprised of 14 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at www.verano.com.

Contacts:
Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
julianna.paterra@verano.com

Media
Verano
Steve Mazeika
VP, Communications
steve.mazeika@verano.com
312-348-4430

###

September 26 2023

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Alexandria LeBlanc Biotech Corner Sep 26th, 2023

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs

• At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression

• No apparent differences in the safety and tolerability profile of SPL026 (DMT) following administration to participants in the SSRI and non-SSRI patient cohorts

LONDON, Sept. 26, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positive safety, tolerability and efficacy data from its Phase Ib study exploring the interaction between selective serotonin reuptake inhibitors (“SSRIs”) and SPL026, native N, N-dimethyltryptamine (“DMT”), in patients with Major Depressive Disorder (“MDD”).

The purpose of this study was to build upon the previously reported Phase I/IIa safety and efficacy profile of SPL026 with support therapy, to assess whether SPL026 can be safely administered with or without SSRIs – the current standard of care for MDD. In the Phase I/IIa SPL026 study, patients were required to be withdrawn from SSRIs, which can be a disruptive experience. Through the SPL026-SSRI drug interaction study, Small Pharma aimed to address this requirement, which could enable broader patient recruitment on future large-scale studies, and potentially accelerate the clinical development pathway. Additionally, removing the requirement to be withdrawn from SSRIs may facilitate patient access to SPL026 earlier in the MDD treatment journey, if approved.

This open-label study investigated the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of a single 27.5 mg intravenous infusion of SPL026, alone or in combination with SSRIs, in 17¹ patients, together with support therapy. The test cohort (N=12) (the “SSRI Cohort”) consisted of patients currently on a stable treatment course of SSRIs, which have been ineffective in fully relieving their depression symptoms. The control cohort (N=5) (the “Non-SSRI Cohort”) consisted of patients not currently using any pharmacological treatment to treat their depression symptoms. Patients were recruited with moderate-severe MDD as defined by a Hamilton Depression Rating Scale (HAM-D) score of >14. Efficacy was assessed using the Montgomery-Asberg Depression Rating scale (MADRS) to measure any change in patients’ depression symptoms from baseline. Additional exploratory endpoints include the Beck Depression Inventory (BDI) to assess patients’ self-reported depression.

Key Results
Safety & Tolerability

SPL026 was well-tolerated by all patients in both the SSRI Cohort and Non-SSRI Cohort, with no apparent differences between cohorts
No drug-related serious adverse events reported
A small number of drug-related adverse events (“AEs”) reported
- 8 in SSRI Cohort
- 3 in Non-SSRI Cohort
- All deemed to be mild or moderate in severity
Majority of drug-related AEs were resolved during the dosing visit

Exploratory Efficacy
The results reaffirmed the efficacy initially demonstrated in the Phase IIa SPL026 study. However, a marked improvement was observed between the antidepressant effect of SPL026 treatment in the SSRI Cohort compared to the Non-SSRI Cohort. While the efficacy observed in the Non-SSRI Cohort was comparable to the efficacy data previously observed in the Company’s SPL026 Phase IIa clinical trial, the antidepressant effects observed in the SSRI Cohort were of a greater magnitude, suggesting a potentially enhanced efficacy effect when SPL026 is administered in combination with SSRIs.

The following chart outlines the efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy:

Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy

Dr. Carol Routledge, Chief Medical and Scientific Officer of Small Pharma, said: “Our primary goal in conducting this Phase Ib study was to understand if SPL026 could be safely administered in conjunction with SSRIs to assess whether patients would need to be withdrawn from their SSRI medication in future trials. While we were very pleased that the study demonstrated that patients may not need to be withdrawn, we were not expecting to see such a marked difference in efficacy when administering SPL026 in combination with SSRIs compared to SPL026 alone. The potentially enhanced efficacy effect of a DMT-based treatment when administered with SSRIs could lead to greater therapeutic benefit for patients, and a compelling argument for positioning it earlier in the treatment pathway. This was a small study, but the findings are both interesting and encouraging and warrant further exploration.”

George Tziras, Chief Executive Officer of Small Pharma, said: “These positive safety and tolerability results further support the patient access strategy for our DMT programs. There may be potential in the future to safely deliver a DMT-based treatment to patients on SSRIs that do not adequately relieve their depression symptoms. Moreover, the marked antidepressant effect seen in the SSRI patient cohort indicates the potential for a combination treatment. We look forward to exploring these findings further as part of the integrated DMT program with Cybin, subject to completion of the proposed arrangement transaction.”

About Small Pharma
Small Pharma is a biotechnology company progressing a pipeline of short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Small Pharma has a portfolio of clinical-stage DMT-based assets, SPL026 and SPL028. The Company was granted an Innovation Passport designation for SPL026 from the U.K. Medicines and Healthcare products Regulatory Agency (the “MHRA”) and has a pipeline of proprietary preclinical assets.

Footnotes:
¹Total study sample of 18. However, 17 participants were evaluable.

Contact Information:
Small Pharma Inc. & Investor Relations:
George Tziras, Chief Executive Officer
Email: ir@smallpharma.co.uk
Tel: +44 (0)7456 915 968

Media Relations:
Jenny Maguire, Head of External Affairs
Email: jenny.maguire@smallpharma.co.uk

Cautionary Note Regarding Forward Looking Statements
This press release contains statements that constitute “forward-looking information” (“forward-looking information”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information.

Forward-looking statements in this news release include statements regarding impacts on the Company’s strategy as a result of the results of the Phase Ib study; the potential enhanced efficacy effect of a DMT-based treatment when administered with SSRIs, and the impact of same, including enabling broader patient recruitment on future large-scale studies, potentially accelerating the clinical development pathway, a greater therapeutic benefit for patients and facilitating patient access to SPL026 earlier in the MDD treatment journey; the potential approval to allow patients; the potential for a combination treatment with SSRIs and SPL026; completion of the proposed arrangement transaction with Cybin; and the Company’s ability to provide short-duration psychedelic-assisted therapies for the treatment of mental health conditions.

In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting the Company’s business and results of operations; the impact of pandemics or other future disruptions; and general business, economic, competitive, political and social uncertainties, and the risk factors set out in each of the Company’s management’s discussion and analysis for the three months ended May 31, 2023, and the Company’s annual information form for the year ended February 28, 2023. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

Small Pharma makes no medical, treatment or health benefit claims about its proposed products. The MHRA or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharma’s performance and operations.

The TSX Venture Exchange (“TSXV”) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16e0c1a8-86b3-4d76-8a4f-184ce02fbe18

Efficacy Chart

Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy

September 26 2023

Fission Announces $8 Million Bought Deal Financing

Alexandria LeBlanc Minning Pit Sep 26th, 2023

TSX SYMBOL: FCU
OTCQX SYMBOL: FCUUF
FRANKFURT SYMBOL: 2FU

KELOWNA, BC, Sept. 26, 2023 /CNW/ – FISSION URANIUM CORP. (“Fission” or the “Company“) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and SCP Resource Finance on behalf of a syndicate of underwriters (collectively, the “Underwriters“), pursuant to which the Underwriters have agreed to purchase, on a “bought deal” basis, 6,722,689 flow-through common shares of the Company (the “Flow-Through Shares“) that will qualify as “flow-through shares” (within the meaning of subsection 66(15) of the Income Tax Act (Canada)) at a price of $1.19 per Flow-Through Share (the “Offering Price“) for gross proceeds of $8,000,000 (the “Offering“).

The Company has granted the Underwriters an option, exercisable at the Offering Price at any time and from time to time for a period of 30 days following the Closing Date (as defined herein), to purchase up to an additional 15% of the number of Flow-Through Shares sold under the Offering to cover over-allotments, if any and for market stabilization purposes. The Offering is expected to close on or about October 4, 2023 (the “Closing Date“) and is subject to the Company receiving all necessary regulatory approvals.

The gross proceeds of the Offering will be used by the Company to incur eligible “Canadian exploration expenses” that will qualify as “flow-through mining expenditures” as such terms are defined in the Income Tax Act (Canada) (the “Qualifying Expenditures“) related to the Company’s PLS project located in Saskatchewan, Canada on or before December 31, 2024. All Qualifying Expenditures will be renounced in favour of the subscribers effective December 31, 2023.

The Flow-Through Shares will be offered by way of a prospectus supplement in each of the Provinces of Canada (other than the Province of Quebec) and may also be offered by way of private placement in the United States and such other jurisdictions as agreed between the parties. The Flow-Through Shares will be issued as charitable flow-through common shares of the Company.

The securities to be offered pursuant to the Offering have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“) or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or any applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Fission Uranium Corp.

Fission Uranium Corp. is an award-winning Canadian-based resource company specializing in uranium exploration and development. The company is the owner and developer of the PLS uranium project – a proposed high-grade mine and mill located in the Athabasca Basin, Saskatchewan, Canada. The company is headquartered in Kelowna, British Columbia. Fission’s common shares are listed on the Toronto Stock Exchange under the symbol “FCU” and trade on the OTCQX marketplace in the U.S. under the symbol “FCUUF.”

ON BEHALF OF THE BOARD

“Ross McElroy”

_________________________
Ross McElroy, President and CEO

Cautionary Statement:
Certain information contained in this press release constitutes “forward-looking information”, within the meaning of Canadian legislation. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur”, “be achieved” or “has the potential to”. Forward looking statements contained in this press release may include statements regarding the use of proceeds of the Offering, the timing for completion of the Offering, the future operating or financial performance of Fission and Fission Uranium which involve known and unknown risks and uncertainties which may not prove to be accurate. Actual results and outcomes may differ materially from what is expressed or forecasted in these forward-looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Among those factors which could cause actual results to differ materially are the following: market conditions and other risk factors listed from time to time in our reports filed with Canadian securities regulators on SEDAR at www.sedar+.com. The forward-looking statements included in this press release are made as of the date of this press release and the Company and Fission Uranium disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation.

SOURCE Fission Uranium Corp.

September 25 2023

Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product

Alexandria LeBlanc Biotech Corner Sep 25th, 2023

NORTHVALE, NJ / ACCESSWIRE / September 25, 2023 / Elite Pharmaceuticals, Inc. (“Elite” or the “Company”)(OTCQB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) on August 17, 2023, and was accepted for review by the US Food and Drug Administration (FDA) on September 19, 2023 for an undisclosed generic drug product in a class of medications called opiate analgesics. IQVIA reported annual sales for the twelve months ending June 2023 of $720 million for the brand and generic market for this product.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite’s product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations
518-398-6222
Dianne@elitepharma.com

SOURCE: Elite Pharmaceuticals, Inc.

September 25 2023

ValOre Drills High-Grade PGE and Nickel-Copper Mineralization 150 m South of Trapia 1, Pedra Branca Project: 71.8 m at 1.59 g/t 2PGE+Au, including 8.15 m at 10.54 g/t 2PGE+Au, 0.37% Ni and 0.11% Cu

Alexandria LeBlanc Minning Pit Sep 25th, 2023

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) — ValOre Drills High-Grade PGE and Nickel-Copper Mineralization 150 m South of Trapia 1, Pedra Branca Project: 71.8 m at 1.59 g/t 2PGE+Au, including 8.15 m at 10.54 g/t 2PGE+Au, 0.37% Ni and 0.11% Cu

Vancouver, British Columbia, September 25^th, 2023 – ValOre Metals Corp. (“ValOre”; TSX‐V: VO; OTCQB: KVLQF; Frankfurt: KEQ0, “the Company”) today reported initial assay results from the recently completed 2023 Phase 1 core drilling at ValOre’s 100%-owned Pedra Branca Platinum Group Elements (“PGE”, “2PGE+Au”) Project (“Pedra Branca”) in northeastern Brazil.

“Drill results from DD23TU33 indicate a broad interval of high-grade mineralization intersected in a 150-metre step out hole to the south of the existing resource at Trapia 1, underscoring the resource expansion potential. Importantly, this broad intersection contains a higher-sulphide, high-grade PGE-Ni-Cu interval that may be amenable to targeting by geophysical methods,” stated Thiago Diniz, Exploration Manager, ValOre Metals Corp. “Trapia 1 results have ramifications at other known zones across the Pedra Branca project, as they clearly demonstrate significant resource expansion potential at depth and down dip of previous drilling.”

Highlights

Trapia 1

Assay results received for the first of four holes drilled in 2023 at the Trapia 1 deposit (total 1,326 m);
- 71.8 metres (“m”) at 1.59 grams per tonne palladium + platinum + gold (“g/t 2PGE+Au”) starting from 235.9 m, including 8.15 m at 10.54 g/t 2PGE+Au, 0.37% Ni and 0.11% Cu;
- High-grade palladium-platinum and nickel-copper mineralization occurs in association with a sulfide-rich peridotitic horizon at the bottom of the chromitite reef, and is characterized by up to 5% disseminated to brecciated pyrrhotite, pyrite, pentlandite and chalcopyrite (Figures 3 and 4);
PGE mineralization intercepted 150 m outside of the existing 2022 NI 43-101 resource at Trapia 1 (480,000 oz of the total Trapia 2022 NI 43-101 resource of 885,000 oz at 0.96 g/t);
Assays pending for the remaining Trapia 1 holes, including DD23TU35 located up-dip of DD23TU33; and DD23TU32, representing an additional 150 m step out to the south, along strike and down-plunge of DD23TU33.

2023 Drill Program

6,152 m drilled in 49 holes distributed along 8 separate exploration and resource zones (see ValOre news release of September 21, 2023);
1,625 core samples sent to lab, with assays pending for 641 samples from 14 holes.
Recently received assays results also include near-surface PGE mineralization drilled in the Ipueiras target, including:
- 11.85 m grading 0.55 g/t 2PGE+Au from surface, incl. 0.9 m grading 1.58 g/t 2PGE+Au from 2.65 m in drill hole DD23IP04;

Table 1: Drilling Totals by Zone

Target	Total Drilled (m)	# Holes	# Holes w/ UMs	Total UMs (m)	Core Samples	Assays Received	Assays Pending
Galante	790	11	11	190	384	384	0
Tróia	1,029	9	6	72	188	188	0
Nambi	665	6	6	74	203	185	18
Ipueiras	228	4	3	27	83	34	49
Massapê	380	4	3	19	48	48	0
Cedro	545	2	1	4	14	14	0
Trapiá South	133	1	1	4	36	36	0
Trapiá 1	1,326	4	4	175	272	95	177
Salvador	1,056	8	7	265	397	0	397
Total	6,152	49	42	830	1,625	984	641

Table 2: Core Assay Highlights (g/t 2PGE+Au) reported today

Target	Hole ID	From (m)	To (m)	Length (m)	2PGE+Au (g/t)	Summary Interval
Trapiá	DD23TU33	235.90	307.70	71.80	1.59	71.8 m @ 1.59 g/t 2PGE+Au from 235.9 m incl. 8.15 m @ 10.54 g/t 2PGE+Au, 0.37% Ni, 0.11% Cu from 258.85 m and 0.6 m @ 46.07 g/t 2PGE+Au from 259.5 m
		258.85	267.00	8.15	10.54
		259.50	260.10	0.60	46.07
Ipueiras	DD23IP04	0.00	11.85	11.85	0.55	11.85 m @ 0.55 g/t 2PGE+Au from surface incl. 0.9 m @ 1.58 g/t 2PGE+Au from 2.65 m
Ipueiras	DD23IP04	2.65	3.55	0.90	1.58

**Reported core assay interval lengths are estimated to represent 90-100% of true width.

230925 VO NR Image 1

Figure 1: Pedra Branca project property map, highlighting locations of the 2023 drill targets and current resource zones (“Trapia” comprises four 2022 NI 43-101 resources zones: Trapia 1, Trapia 2, Trapia West and Trapia South).

230925 VO NR Image 2

Figure 2: Trapiá 1 Deposit long section (looking NE) highlighting location of drill hole DD23TU33 (today’s release) and the 300 m step out drilling at DD23TU32, for which assays are pending.

230925 VO NR Image 3

Figure 3: Core photographs of the high-grade PGE zone intercepted in drill hole DD23TU33. Mineralization hosted within chromite reef and sulfide-rich peridotites.

230925 VO NR Image 4

Figure 4: Detailed core photographs of high-grade PGE-(Ni-Cu) mineralized peridotites (left) and >40 g/t 2PGE+Au chromitite reef (right) intercepted in diamond drill hole DD23TU33.

Quality Assurance/Quality Control (“QA/QC”)

CLICK HERE for a summary of ValOre’s policies and procedures related to QA/QC and grade interval reporting.

Qualified Person (“QP”)

The technical information in this news release has been prepared in accordance with Canadian regulatory requirements set out in NI 43-101 and reviewed and approved by Thiago Diniz, P.Geo., ValOre’s QP and Exploration Manager.

About ValOre Metals Corp.

ValOre Metals Corp. (TSX‐V: VO) is a Canadian company with a team aiming to deploy capital and knowledge on projects which benefit from substantial prior investment by previous owners, existence of high-value mineralization on a large scale, and the possibility of adding tangible value through exploration and innovation.

ValOre’s Pedra Branca Platinum Group Elements Project comprises 52 exploration licenses covering a total area of 56,852 hectares (140,484 acres) in northeastern Brazil. At Pedra Branca, 7 distinct PGE+Au deposit areas host, in aggregate, a 2022 NI 43-101 inferred resource of 2.198 Moz 2PGE+Au contained in 63.6 Mt grading 1.08 g/t 2PGE+Au (CLICK HERE for news release dated March 24, 2022). ValOre’s team believes the Pedra Branca project has significant exploration discovery and resource expansion potential.

On behalf of the Board of Directors,

“Jim Paterson”

James R. Paterson, Chairman and CEO

ValOre Metals Corp.

For further information about ValOre Metals Corp., or this news release, please visit our website at www.valoremetals.com or contact Investor Relations at contact@valoremetals.com.

ValOre Metals Corp. is a proud member of Discovery Group. For more information please visit: http://www.discoverygroup.ca/

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains “forward-looking statements” within the meaning of applicable securities laws. Although ValOre believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to ValOre. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. A number of important factors including those set forth in other public filings could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include the future operations of ValOre and economic factors. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this press release are made as of the date of this release and, except as required by applicable law, ValOre does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. ValOre undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of ValOre, or its financial or operating results or (as applicable), their securities.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/2011adf5-4db0-4bee-84d7-9688438287f3

https://www.globenewswire.com/NewsRoom/AttachmentNg/962a2361-2df6-4619-887f-f66993e09d42

https://www.globenewswire.com/NewsRoom/AttachmentNg/eea015ad-8a11-4f7f-8ee5-acd54d4191d9

https://www.globenewswire.com/NewsRoom/AttachmentNg/fc143ff3-14ce-434e-894c-5bd17242cbfe

Pedra Branca Project Property

Figure 1: Pedra Branca project property map, highlighting locations of the 2023 drill targets and current resource zones (“Trapia” comprises four 2022 NI 43-101 resources zones: Trapia 1, Trapia 2, Trapia West and Trapia South).

Trapiá 1 Deposit

Figure 2: Trapiá 1 Deposit long section (looking NE) highlighting location of drill hole DD23TU33 (today’s release) and the 300 m step out drilling at DD23TU32, for which assays are pending.

Core Photographs

Figure 3: Core photographs of the high-grade PGE zone intercepted in drill hole DD23TU33. Mineralization hosted within chromite reef and sulfide-rich peridotites.

Detailed Core Photographs

Figure 4: Detailed core photographs of high-grade PGE-(Ni-Cu) mineralized peridotites (left) and >40 g/t 2PGE+Au chromitite reef (right) intercepted in diamond drill hole DD23TU33.

Efficacy Chart

Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy

Pedra Branca Project Property

Figure 1: Pedra Branca project property map, highlighting locations of the 2023 drill targets and current resource zones (“Trapia” comprises four 2022 NI 43-101 resources zones: Trapia 1, Trapia 2, Trapia West and Trapia South).

Trapiá 1 Deposit

Figure 2: Trapiá 1 Deposit long section (looking NE) highlighting location of drill hole DD23TU33 (today’s release) and the 300 m step out drilling at DD23TU32, for which assays are pending.

Core Photographs

Figure 3: Core photographs of the high-grade PGE zone intercepted in drill hole DD23TU33. Mineralization hosted within chromite reef and sulfide-rich peridotites.

Detailed Core Photographs

Figure 4: Detailed core photographs of high-grade PGE-(Ni-Cu) mineralized peridotites (left) and >40 g/t 2PGE+Au chromitite reef (right) intercepted in diamond drill hole DD23TU33.

NEWSLETTER